Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Key Points

• Reviva saw an unusual surge in options activity as traders bought 27,891 call options on Tuesday, a 458% increase versus the stock's average call volume of 5,000.
• Institutional ownership is high at 63.18%, with several funds adding or increasing positions recently — notably Persistent Asset Partners boosted its stake by 300% to 641,174 shares.
• Analysts hold a consensus rating of “Moderate Buy” with a $3.86 target, while the stock trades around $0.68 with a ~$78 million market cap and negative earnings.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw unusually large options trading activity on Tuesday. Traders acquired 27,891 call options on the stock. This represents an increase of 458% compared to the average volume of 5,000 call options.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth about $31,000. Lido Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the third quarter worth approximately $37,000. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the first quarter valued at approximately $58,000. Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company's stock worth $171,000 after purchasing an additional 29,063 shares during the period. Finally, Persistent Asset Partners Ltd lifted its holdings in Reviva Pharmaceuticals by 300.0% during the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock worth $244,000 after purchasing an additional 480,864 shares during the last quarter. Institutional investors and hedge funds own 63.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. D. Boral Capital restated a "buy" rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Wednesday, November 19th. HC Wainwright reduced their price target on Reviva Pharmaceuticals from $11.00 to $4.00 and set a "buy" rating for the company in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a "sell" rating in a report on Saturday, October 4th. Maxim Group reduced their target price on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a "buy" rating for the company in a report on Friday, August 15th. Finally, Citigroup reaffirmed a "buy" rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Reviva Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $3.86.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH traded up $0.05 during mid-day trading on Tuesday, hitting $0.68. The stock had a trading volume of 5,147,133 shares, compared to its average volume of 3,967,345. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $2.99. The stock has a market cap of $78.01 million, a price-to-earnings ratio of -1.47 and a beta of -0.02. The company's 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.54.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.05. As a group, equities analysts forecast that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.